BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Bolt Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$4.04+0.04 (+1.00%)
Close on Oct 19, 2026
- Market cap
- $6.83M
- P/E (TTM)
- –
- Dividend yield
- –
Bolt Biotherapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Bolt Biotherapeutics | Industry median |
|---|---|---|
| Market Cap | $7.78M | $197.05M |
| Enterprise Value | -$10.32M | $106.56M |
| PS Ratio | 1.66 | 3.93 |
| PB Ratio | 0.62 | 2.14 |
| P/TBV Ratio | 0.62 | 2.46 |
Enterprise value
| Measure | Bolt Biotherapeutics | Industry median |
|---|---|---|
| EV / Sales | -2.20 | 2.69 |
Income (trailing twelve months)
| Measure | Bolt Biotherapeutics | Industry median |
|---|---|---|
| Revenue | $4.70M | $57.94M |
| Operating Income | -$30.76M | -$21.44M |
| Net Income | -$28.74M | -$22.46M |
| EBITDA | -$29.84M | -$16.91M |
| EPS (Diluted) | -$16.44 | -$0.83 |
Margins
| Measure | Bolt Biotherapeutics | Industry median |
|---|---|---|
| Operating Margin | -654.5% | -44.5% |
| Profit Margin | -611.5% | -39.2% |
| EBITDA Margin | -635.0% | -31.3% |
Returns
| Measure | Bolt Biotherapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -111.6% | -53.1% |
| Return on Assets (ROA) | -49.6% | -41.0% |
| Return on Capital Employed (ROCE) | -94.7% | -37.8% |
Growth
| Measure | Bolt Biotherapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 12.8% | 6.01% |
| Revenue Growth (3Y CAGR) | 10.3% | 2.25% |
| Revenue Growth (5Y CAGR) | 101.6% | 6.42% |
Balance sheet
| Measure | Bolt Biotherapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $18.10M | $62.42M |
| Net Cash (Debt) | $18.10M | $15.68M |
| Net Cash Per Share | $9.40 | $0.65 |
| Equity (Book Value) | $12.64M | $48.79M |
| Book Value Per Share | $6.56 | $1.36 |
| Tangible Book Value | $12.64M | $23.06M |
| Working Capital | $12.70M | $75.77M |
Financial position
| Measure | Bolt Biotherapeutics | Industry median |
|---|---|---|
| Current Ratio | 2.61 | 3.30 |
| Quick Ratio | 2.30 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Bolt Biotherapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$31.45M | -$12.35M |
Efficiency
| Measure | Bolt Biotherapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.08 | 0.38 |
| Revenue Per Employee | $204.35K | $398.96K |
| Profits Per Employee | -$1.25M | -$732.08K |
| Employee Count | 23 | 73 |
Dividends and yields
| Measure | Bolt Biotherapeutics | Industry median |
|---|---|---|
| Earnings Yield | -369.3% | -21.2% |
| Buyback Yield | -0.39% | -0.58% |
| Shareholder Yield | -0.39% | 0.00% |
Shares
| Measure | Bolt Biotherapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 1,926,350 | 59,128,900 |
| Shares Change (YoY) | -8.42% | 11.1% |
| Shares Change (QoQ) | 0.25% | 0.54% |
| Float | 1,777,920 | 48,744,500 |
| Shares Held by Insiders | 7.70% | 11.8% |
| Shares Held by Institutions | 31.0% | 59.4% |
Scores
| Measure | Bolt Biotherapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -18.36 | 0.10 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Bolt Biotherapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.